Chengdu Pioneer Drug Development Co., Ltd. announced a multi-year, long-term, new drug research and development collaboration with Aduro Biotech to achieve a new small molecule lead compound for these targets.
According to the cooperation agreement, Chengdu Pilot will use its DNA coding compound library (DEL) design, synthesis and screening of the core technology platform, the screening of the lead compounds exclusive transfer to Aduro. Aduro will pay the down payment and follow-up milestone to the Chengdu pilot in accordance with the agreement.
“Aduro is a leading global biotech company in the field of tumor immunity and we will work closely with Aduro researchers to promote the birth of new and more effective treatment programs,” said Dr. Li Jin, Chairman and CEO of Chengdu Leader. Benefit the patient. “
About Chengdu pilot
Chengdu Pilot is an innovative drive biotechnology company. Headquartered in Chengdu, China, in the United States have laboratories. Chengdu Pilot has established a unique early drug discovery platform, the DNA coding compound library design and screening technology. At present, Chengdu pilot based on hundreds of different skeletal structure, has completed more than 85 billion new structure, with diversity and drug-like DNA encoding compounds synthesis, and there have been a number of cases confirmed its target for the target and emerging targets The ability to screen for signs of compounds. Chengdu Pilot has been working with a number of pharmaceutical, biotechnology companies and research institutions to develop and develop new treatment programs.
For more information, please contact:
Dr. Li Jin, Chairman and CEO,
Chengdu Pilot Pharmaceutical Development Co., Ltd.
Tel: +86 28 85197385 (extension 8001)
Dr. Barry Morgan, Chief Scientist,
Chengdu Pilot Pharmaceutical Development Co., Ltd.
Tel: +1 5088409646
